Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

US Patent and Option Agreement

21 Dec 2009 07:00

RNS Number : 4201E
Byotrol PLC
21 December 2009
 



2December 2009

Byotrol plc

New patent and option agreement

The Board of Byotrol plc ('Byotrol' or the 'Company') is pleased to announce some positive developments.

 

A United States patent has now been accepted for the Company's antimicrobial technology with the US Patent  Office sending a Letter of Allowance for patent application number 10/039677. This application, which  commenced in 2002, provides patent protection until 2022 in one of our major markets. 

The Board is also pleased to announce that, together with its joint venture partner Byotrol Consumer Products Limited ("BCP"), the company has entered into a six month option agreement, which is extendable by three months, with a Fortune 150 corporation with broad international operations. This agreement is for exclusive rights to enter into negotiations for a licensing arrangement for Byotrol's patented technology.

The principal terms of the agreement cover Byotrol's technology in the fields of pre-saturated wipes and of liquids for certain surface care markets and specifically excludes all currently contracted areas of business. The counterparty has agreed to pay Byotrol and BCP jointly a non refundable sum of US$250,000 as consideration for the option, with additional sums being payable if the option extends beyond six months

Commenting on the developments, David McRobbie, Chief Executive of Byotrol said:

"The USA is the world's largest market for technologies such as ours and having a granted US patent as well as several ongoing applications both there and in the rest of the world is an important platform for our licensing model.

"Further, we are pleased that multinational consumer companies are now increasing their interest in the Byotrol technology. At this very early stage there is no guarantee that this particular agreement will lead to any formal supply agreements, but it is an important step forward for the Company."

Enquiries:

David McRobbie, Chief Executive 0161 277 9518

Stephen Falder, Deputy Chairman

Richard Bell, Finance Director

Philip Davies / Carl Holmes 020 7149 6000

Charles Stanley Securities

Nominated Adviser

Tom Cooper / Paul Vann 020 3043 4162

Winningtons 0797 122 1972

Notes to Editors

Byotrol Plc (BYOT.L), quoted on AIM, is a leading microbial technology hygiene company, operating globally in the Health, Food, Leisure, Consumer, Industrial and Agriculture sectors, providing a low toxicity product with a broad-based and long lasting efficacy across all microbial classes; bacteria, viruses, fungi, moulds, microbacteria and algae. 

The Byotrol product can be used as a stand alone product or as a complementary biocide additive to existing products to improve their performance in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

Founded in 2005, the Company has prioritised the development of a technology that creates easier, safer and cleaner lives through partnering with providers of essential goods and services. Byotrol is the catalyst behind the aptly named global 'Hygiene Revolution'.

For more information, please go to www.byotrol.co.uk 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAUWUNRKVRUAAA
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.